
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (18): 2577-2584.DOI: 10.12114/j.issn.1007-9572.2024.0677
• Review & Perspectives • Previous Articles Next Articles
Received:2025-01-10
Revised:2025-10-20
Published:2026-06-20
Online:2026-05-21
Contact:
YAN Rui
通讯作者:
严瑞
作者简介:作者贡献:
简迎春负责研究命题的提出、论文撰写;曾永秦负责论文修改;张海平负责检索和整理;王争地、安科负责论文润色;严瑞负责文章的质量控制及监督管理。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0677
| 线粒体功能障碍类型 | 关联疾病及引用文献 | 关键机制 |
|---|---|---|
| ROS过度生成 | AD[ | ROS过量导致氧化应激,损伤细胞和组织,促进炎症反应和疾病进展。 |
| 线粒体自噬受损 | AD[ | 受损线粒体无法被清除,导致ROS积累和能量代谢障碍,进一步加重细胞损伤 |
| mtDNA突变或受损 | AD[ | mtDNA突变或损伤导致线粒体功能异常,影响能量生成和细胞稳态,促进疾病发展 |
| 生物发生异常 | HD[ | 线粒体生物发生受阻,导致线粒体数量减少和功能下降,影响能量代谢和组织功能 |
| 钙稳态失衡 | HD[ | 线粒体钙摄取和释放失衡,导致细胞功能紊乱,影响能量代谢和细胞存活 |
| 能量失衡 | HD[ | 线粒体能量生成不足,导致细胞能量供应不足,影响组织功能和代谢平衡 |
| 线粒体裂变增加 | AS[ | 线粒体过度裂变导致线粒体碎片化,功能受损,影响细胞能量代谢和组织功能 |
Table 1 Relationship between chronic metabolic diseases and mitochondrial dysfunction
| 线粒体功能障碍类型 | 关联疾病及引用文献 | 关键机制 |
|---|---|---|
| ROS过度生成 | AD[ | ROS过量导致氧化应激,损伤细胞和组织,促进炎症反应和疾病进展。 |
| 线粒体自噬受损 | AD[ | 受损线粒体无法被清除,导致ROS积累和能量代谢障碍,进一步加重细胞损伤 |
| mtDNA突变或受损 | AD[ | mtDNA突变或损伤导致线粒体功能异常,影响能量生成和细胞稳态,促进疾病发展 |
| 生物发生异常 | HD[ | 线粒体生物发生受阻,导致线粒体数量减少和功能下降,影响能量代谢和组织功能 |
| 钙稳态失衡 | HD[ | 线粒体钙摄取和释放失衡,导致细胞功能紊乱,影响能量代谢和细胞存活 |
| 能量失衡 | HD[ | 线粒体能量生成不足,导致细胞能量供应不足,影响组织功能和代谢平衡 |
| 线粒体裂变增加 | AS[ | 线粒体过度裂变导致线粒体碎片化,功能受损,影响细胞能量代谢和组织功能 |
| 治疗策略 | 具体方法/药物 | 作用机制 | 适用疾病 | 参考文献 |
|---|---|---|---|---|
| 促进线粒体生物发生 | 间歇性禁食 | 激活线粒体生物发生相关信号通路,改善生物能量学 | HD | [ |
| 烟酰胺核苷、三萜类化合物 | 促进线粒体生物发生,改善线粒体功能 | 线粒体肌病 | [ | |
| 利西那肽 | 促进线粒体生物发生,改善2型糖尿病患者的代谢 | 2型糖尿病 | [ | |
| 二甲双胍 | 刺激线粒体生物发生和脂肪酸氧化,改善NAFLD | 2型糖尿病、NAFLD | [ | |
| SIRT1激活剂 | 促进线粒体生物发生,对抗肥胖相关的炎症反应 | 肥胖症 | [ | |
| 抗氧化应激 | 辅酶Q10 | 清除ROS,改善内皮功能和血脂水平,减轻糖尿病患者的高血糖症状 | AS、DM | [ |
| 肼屈嗪 | 预防氧化应激,减缓AD进展 | AD | [ | |
| N-乙酰半胱氨酸、维生素E | 保护线粒体免受氧化损伤,改善HD症状 | HD | [ | |
| 调控线粒体动力学 | 半胱氨酸天冬氨酸蛋白水解酶1抑制剂 | 促进线粒体自噬,AS | AS | [ |
| 亚精胺 | 诱导自噬,改善AD小鼠模型的疾病进展 | AD | [ | |
| 尿石素A | 增加线粒体自噬,减轻神经炎症,增强小胶质细胞吞噬作用 | AD | [ | |
| 恩格列净 | 调节线粒体裂变和融合蛋白,使糖尿病大鼠心肌细胞ATP合成增加,同时降低ROS水平 | DM | [ | |
| 改善线粒体膜功能 | ω-3脂肪酸 | 嵌入线粒体膜,增强膜流动性,减少炎症反应,改善认知功能 | AD | [ |
| 磷脂酰丝氨酸 | 稳定线粒体膜,增加流动性,保护神经 | AD | [ | |
| 其他新兴疗法 | 线粒体移植 | 用正常功能的线粒体替换受损线粒体,恢复ATP生成,减少ROS产生 | 糖尿病心肌缺血、精神疾病 | [ |
| mtDNA编辑疗法 | 通过编辑mtDNA修复突变或缺失,治疗线粒体遗传疾病 | 线粒体遗传疾病 | [ | |
| mtDNA替代疗法 | 使用健康mtDNA替换缺陷mtDNA,预防线粒体母系遗传疾病 | 线粒体母系遗传疾病 | [ | |
| 纳米技术 | 利用纳米载体靶向线粒体,实现药物高效输送 | 肿瘤、自身免疫性疾病 | [ | |
| 嵌合抗原受体T细胞免疫疗法 | 识别和攻击线粒体功能障碍细胞,提供新的治疗策略 | 肿瘤、自身免疫性疾病 | [ |
Table 2 Treatment of mitochondrial dysfunction
| 治疗策略 | 具体方法/药物 | 作用机制 | 适用疾病 | 参考文献 |
|---|---|---|---|---|
| 促进线粒体生物发生 | 间歇性禁食 | 激活线粒体生物发生相关信号通路,改善生物能量学 | HD | [ |
| 烟酰胺核苷、三萜类化合物 | 促进线粒体生物发生,改善线粒体功能 | 线粒体肌病 | [ | |
| 利西那肽 | 促进线粒体生物发生,改善2型糖尿病患者的代谢 | 2型糖尿病 | [ | |
| 二甲双胍 | 刺激线粒体生物发生和脂肪酸氧化,改善NAFLD | 2型糖尿病、NAFLD | [ | |
| SIRT1激活剂 | 促进线粒体生物发生,对抗肥胖相关的炎症反应 | 肥胖症 | [ | |
| 抗氧化应激 | 辅酶Q10 | 清除ROS,改善内皮功能和血脂水平,减轻糖尿病患者的高血糖症状 | AS、DM | [ |
| 肼屈嗪 | 预防氧化应激,减缓AD进展 | AD | [ | |
| N-乙酰半胱氨酸、维生素E | 保护线粒体免受氧化损伤,改善HD症状 | HD | [ | |
| 调控线粒体动力学 | 半胱氨酸天冬氨酸蛋白水解酶1抑制剂 | 促进线粒体自噬,AS | AS | [ |
| 亚精胺 | 诱导自噬,改善AD小鼠模型的疾病进展 | AD | [ | |
| 尿石素A | 增加线粒体自噬,减轻神经炎症,增强小胶质细胞吞噬作用 | AD | [ | |
| 恩格列净 | 调节线粒体裂变和融合蛋白,使糖尿病大鼠心肌细胞ATP合成增加,同时降低ROS水平 | DM | [ | |
| 改善线粒体膜功能 | ω-3脂肪酸 | 嵌入线粒体膜,增强膜流动性,减少炎症反应,改善认知功能 | AD | [ |
| 磷脂酰丝氨酸 | 稳定线粒体膜,增加流动性,保护神经 | AD | [ | |
| 其他新兴疗法 | 线粒体移植 | 用正常功能的线粒体替换受损线粒体,恢复ATP生成,减少ROS产生 | 糖尿病心肌缺血、精神疾病 | [ |
| mtDNA编辑疗法 | 通过编辑mtDNA修复突变或缺失,治疗线粒体遗传疾病 | 线粒体遗传疾病 | [ | |
| mtDNA替代疗法 | 使用健康mtDNA替换缺陷mtDNA,预防线粒体母系遗传疾病 | 线粒体母系遗传疾病 | [ | |
| 纳米技术 | 利用纳米载体靶向线粒体,实现药物高效输送 | 肿瘤、自身免疫性疾病 | [ | |
| 嵌合抗原受体T细胞免疫疗法 | 识别和攻击线粒体功能障碍细胞,提供新的治疗策略 | 肿瘤、自身免疫性疾病 | [ |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [1] | WANG Yang, ZHAO Shiting, CHEN Yingying, SUN Zilin, QIU Shanhu. Key Points of Exercise Intervention and Implementation for People with Complications of Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(21): 2989-2994. |
| [2] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [3] | LI Jiawei, GAO Xinyi, GE Aoqi, LI Juanjuan, YUAN Beibei. Demand and Associated Factors for Integrated Medical Care and Preventive Services among Patients with Type 2 Diabetes [J]. Chinese General Practice, 2026, 29(21): 3028-3039. |
| [4] | PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988. |
| [5] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [6] | ZHANG Xiaojuan, LIU Yang, PENG Bo, YE Yuan, ZHU Kun. Study on the Prevention and Treatment of Hypertension and Diabetes Mellitus in Community Hospital [J]. Chinese General Practice, 2026, 29(19): 2614-2620. |
| [7] | LIU Daiyue, LIU Xincan, LAN Zhenzhen. Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches [J]. Chinese General Practice, 2026, 29(18): 2546-2553. |
| [8] | MIAO Jingjie, ZHANG Jinwen, WU Qianhao, HAN Peipei. Research Advances on the Effects of Intermittent Fasting on Cardiometabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2538-2545. |
| [9] | LI Yachan, YANG Yang, XU Qianting, KE Tingyu. Association between the Chinese Visceral Adiposity Index and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(18): 2482-2488. |
| [10] | LI Menglin, DING Fang, QIAN Yu, PU Dong, DU Qianqian, GUAN Tianhang, HE Yilin. Study on Glycemic Control Status and Influencing Factors among Community Diabetic Patients [J]. Chinese General Practice, 2026, 29(17): 2334-2339. |
| [11] | WANG Rui, LUO Dan, YANG Cuicui, WENG Xinyi, WANG Yubing, XU Jingjing. Complex Network Analysis of Resilience in Adolescents with Type 1 Diabetes Mellitus Based on Multi-sourced Stigma [J]. Chinese General Practice, 2026, 29(16): 2264-2272. |
| [12] | FU Mingyuan, YU Xiaoyi, GE Caiying, KONG Min. Impaired Awareness of Hypoglycemia: Prevalence and Determinants among Community-based Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(16): 2252-2258. |
| [13] | JIN Chunhua, ZHANG Yawen, LI Lianxi. Association between Serum Bilirubin Within the Normal Range and Carotid Plaques in Elderly Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(15): 1986-1991. |
| [14] | YU Jie, WU Chunxiang, CAI Ning, ZHU Xiaoxia, SHEN Li. Study on Multidimensional Healthcare-seeking Behavior Patterns and Influencing Factors in Diabetic Patients [J]. Chinese General Practice, 2026, 29(14): 1827-1839. |
| [15] | SONG Lu, LAN Zhigang, ZHOU Wei, FENG Liping, LIU Yunqiu, CHEN Shuohua, WANG Liye. Correlation Study between Diabetes Mellitus and Lung Function in Male People [J]. Chinese General Practice, 2026, 29(12): 1572-1578. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||